Compare Eli Lilly And Co (LLY) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MasTec Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: Eli Lilly And Co is far larger — about 59.8× MasTec Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and MasTec Inc for 23 Days on average.
| LLY | MTZ | |
|---|---|---|
Market Cap | $1.04T | $17.40B |
Volume | 3,064,878 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $1.28K | $437.51 |
52-Week Low | $799.57 | $190.08 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $1.09T | $20.32B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, with technical indicators showing bearish momentum as the stock trades below key moving averages. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, while maintaining robust revenue growth projections for 2026. Analyst sentiment remains overwhelmingly positive with 89% buy ratings and a consensus price target of $408.58, representing significant upside potential from current levels.
MTZ presents a compelling growth story with record $21.4B backlog and exposure to infrastructure investment cycles, though premium valuation metrics and recent cash flow weakness warrant caution. The stock's current discount to analyst targets offers opportunity, but execution risks in communications segment and competitive pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
